|
1
|
Chen Y, Yu D, Zhang W, Qiu C, Xiang G, Dai
W, Wu S and Wang X: HBV subgenotype C2 infection, A1762T/G1764A
mutations may contribute to hepatocellular carcinoma with cirrhosis
in Southeast China. Iran J Public Health. 41:10–18. 2012.PubMed/NCBI
|
|
2
|
Gao JD, Shao YF, Xu Y, Ming LH, Wu ZY, Liu
GT, Wang XH, Gao WH, Sun YT, Feng XL, Liang LM, Zhang YH and Sun
ZT: Tight association of hepatocellular carcinoma with HBV
infection in North China. Hepatobiliary Pancreat Dis Int. 4:46–49.
2005.PubMed/NCBI
|
|
3
|
Ye SL: Expert consensus on standardization
of the management of primary liver cancer. Zhonghua Gan Zang Bing
Za Zhi. 17:403–410. 2009.(In Chinese).
|
|
4
|
Song MJ and Bae SH: Newer treatments for
advanced hepatocellular carcinoma. Korean J Intern Med. 29:149–155.
2014. View Article : Google Scholar
|
|
5
|
Hu M, Zhao M, An C, Yang M, Li Q, Zhang Y,
Suetsugu A, Tome Y, Yano S, Fu Y, Hoffman RM and Hu K: Real-time
imaging of apoptosis induction of human breast cancer cells by the
traditional Chinese medicinal herb Tubeimu. Anticancer Res.
32:2509–2514. 2012.PubMed/NCBI
|
|
6
|
Tang WM, Chan E, Kwok CY, Lee YK, Wu JH,
Wan CW, Chan RY, Yu PH and Chan SW: A review of the anticancer and
immunomodulatory effects of Lycium barbarum fruit.
Inflammopharmacology. 20:307–314. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Park BH, Jung KH, Son MK, Seo JH, Lee HS,
Lee JH and Hong SS: Antitumor activity of Pulsatilla koreana
extract in anaplastic thyroid cancer via apoptosis and
anti-angiogenesis. Mol Med Rep. 7:26–30. 2013.
|
|
8
|
Cao Z, Liao L, Chen X, Lan L, Hu H, Liu Z,
Chen L, Huang S and Du J: Enhancement of antitumor activity of
low-dose 5-fluorouracil by combination with Fuzheng-Yiliu granules
in hepatoma 22 tumor-bearing mice. Integr Cancer Ther. 12:174–181.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Cao Z, Lin W, Huang Z, Chen X, Zhao J,
Zheng L, Ye H, Liu Z, Liao L and Du J: Ethyl acetate extraction
from a Chinese herbal formula, Jiedu Xiaozheng Yin, inhibits the
proliferation of hepatocellular carcinoma cells via induction of
G0/G1 phase arrest in vivo and in vitro. Int J Oncol.
42:202–210. 2013.PubMed/NCBI
|
|
10
|
Wong R, Sagar CM and Sagar SM: Integration
of Chinese medicine into supportive cancer care: A modern role for
an ancient tradition. Cancer Treat Rev. 27:235–246. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Qi F, Li A, Inagaki Y, Gao J, Li J, Kokudo
N, Li XK and Tang W: Chinese herbal medicines as adjuvant treatment
during chemo-or radio-therapy for cancer. Biosci Trends. 4:297–307.
2010.PubMed/NCBI
|
|
12
|
Li X, Yang G, Li X, Zhang Y, Yang J, Chang
J, Sun X, Zhou X, Guo Y, Xu Y, Liu J and Bensoussan A: Traditional
Chinese medicine in cancer care: a review of controlled clinical
studies published in Chinese. PLoS One. 8:e603382013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wang L, Zhou GB, Liu P, Song JH, Liang Y,
Yan XJ, Xu F, Wang BS, Mao JH, Shen ZX, Chen SJ and Chen Z:
Dissection of mechanisms of Chinese medicinal formula
Realgar-Indigo naturalis as an effective treatment for
promyelocytic leukemia. Proc Natl Acad Sci USA. 105:4826–4831.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kuo YJ, Yang JS, Lu CC, Chiang SY, Lin JG
and Chung JG: Ethanol extract of Hedyotis diffusa willd
upregulates G0/G1 phase arrest and induces apoptosis in human
leukemia cells by modulating caspase cascade signaling and altering
associated genes expression was assayed by cDNA microarray. Environ
Toxicol. Mar 28–2014.(Epub ahead of print). View Article : Google Scholar
|
|
15
|
Chang C, Liu SP, Fang CH, He RS, Wang Z,
Zhu YQ and Jiang SW: Effects of matrine on the proliferation of
HT29 human colon cancer cells and its antitumor mechanism. Oncol
Lett. 6:699–704. 2013.PubMed/NCBI
|
|
16
|
Feng L, Jia X, Zhu M, Chen Y and Shi F:
Chemoprevention by Prunella vulgaris L. extract of non-small
cell lung cancer via promoting apoptosis and regulating the cell
cycle. Asian Pac J Cancer Prev. 11:1355–1358. 2010.
|
|
17
|
Dong H, Guo S, Wang C, Yang J and Xiao P:
Advances in studies on chemical constituents in plants of
Pseudobulbus Cremastrae seu Pleiones and their
pharmacological activities. Zhong Cao Yao. 38:1734–1738. 2007.(In
Chinese).
|
|
18
|
Chen LW, Lin J, Chen W and Zhang W: Effect
of Chinese herbal medicine on patients with primary hepatic
carcinoma in III stage during perioperational period: a report of
42 cases. Zhongguo Zhong Xi Yi Jie He Za Zhi. 25:832–834. 2005.(In
Chinese).
|
|
19
|
Cao Z, Lin W, Huang Z, Chen X, Zhao J,
Zheng L, Ye H, Liu Z, Liao L and Du J: Jiedu Xiaozheng Yin, a
Chinese herbal formula, inhibits tumor angiogenesis via
down-regulation of VEGF-A and VEGFR-2 expression in vivo and
in vitro. Oncol Rep. 29:1083–1086. 2013.PubMed/NCBI
|
|
20
|
Cao Z, Chen X, Lin Y and Du J: Effect of
Chinese compound prescription on expressions of c-kit and CD133 of
tumor stem cell in mice of hepatocellular carcinoma transplanted
subcutaneously. Fujian J Tradit Chin Med. 20:18–21. 2010.(In
Chinese).
|
|
21
|
Chiba T, Miyagi S, Saraya A, Aoki R, Seki
A, Morita Y, Yonemitsu Y, Yokosuka O, Taniguchi H, Nakauchi H and
Iwama A: The polycomb gene product Bmi1 contributes to the
maintenance of tumor-initiating side population cells in
hepatocellular carcinoma. Cancer Res. 68:7742–7749. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Reya T and Clevers H: Wnt signalling in
stem cells and cancer. Nature. 434:843–850. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Clarke MF, Dick JE, Dirks PB, Eaves CJ,
Jamieson CH, Jones DL, Visvader J, Weissman IL and Wahl GM: Cancer
stem cells - perspectives on current status and future directions:
AACR Workshop on Cancer Stem Cells. Cancer Res. 66:9339–9344. 2006.
View Article : Google Scholar
|
|
24
|
Shtutman M, Zhurinsky J, Simcha I,
Albanese C, D’Amico M, Pestell R and Ben-Ze’ev A: The cyclin D1
gene is a target of the β-catenin/LEF-1 pathway. Proc Natl Acad Sci
USA. 96:5522–5527. 1999.
|
|
25
|
Pagano M, Theodoras AM, Tam SW and Draetta
GF: Cyclin D1-mediated inhibition of repair and replicative DNA
synthesis in human fibroblasts. Genes Dev. 8:1627–1639. 1994.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Li X, Yang Z, Song W, Zhou L, Li Q, Tao K,
Zhou J, Wang X, Zheng Z, You N, Dou K and Li H: Overexpression of
Bmi-1 contributes to the invasion and metastasis of hepatocellular
carcinoma by increasing the expression of matrix metalloproteinase
(MMP)-2, MMP-9 and vascular endothelial growth factor via the
PTEN/PI3K/Akt pathway. Int J Oncol. 43:793–802. 2013.PubMed/NCBI
|
|
27
|
Effendi K, Mori T, Komuta M, Masugi Y, Du
W and Sakamoto M: Bmi-1 gene is upregulated in early-stage
hepatocellular carcinoma and correlates with ATP-binding cassette
transporter B1 expression. Cancer Sci. 101:666–672. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wang H, Pan K, Zhang HK, Weng DS, Zhou J,
Li JJ, Huang W, Song HF, Chen MS and Xia JC: Increased
polycomb-group oncogene Bmi-1 expression correlates with poor
prognosis in hepatocellular carcinoma. J Cancer Res Clin Oncol.
134:535–541. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Steele JC, Torr EE, Noakes KL, Kalk E,
Moss PA, Reynolds GM, Hubscher SG, van Lohuizen M, Adams DH and
Young LS: The polycomb group proteins, BMI-1 and EZH2, are
tumour-associated antigens. Br J Cancer. 95:1202–1211. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Jacobs JJ, Kieboom K, Marino S, DePinho RA
and van Lohuizen M: The oncogene and Polycomb-group gene bmi-1
regulates cell proliferation and senescence through the ink4a
locus. Nature. 397:164–168. 1999. View
Article : Google Scholar : PubMed/NCBI
|
|
31
|
Hui AM, Sakamoto M, Kanai Y, Ino Y, Gotoh
M, Yokota J and Hirohashi S: Inactivation of p16INK4 in
hepatocellular carcinoma. Hepatology. 24:575–579. 1996. View Article : Google Scholar
|
|
32
|
Micsenyi A, Tan X, Sneddon T, Luo JH,
Michalopoulos GK and Monga SP: β-catenin is temporally regulated
during normal liver development. Gastroenterology. 126:1134–1146.
2004.
|
|
33
|
Arend RC, Londoño-Joshi AI, Straughn JM Jr
and Buchsbaum DJ: The Wnt/β-catenin pathway in ovarian cancer: a
review. Gynecol Oncol. 131:772–779. 2013.
|
|
34
|
Rakheja D, Cunningham JC, Mitui M, Patel
AS, Tomlinson GE and Weinberg AG: A subset of cranial fasciitis is
associated with dysregulation of the Wnt/beta-catenin pathway. Mod
Pathol. 21:1330–1336. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Ikeda S, Kishida S, Yamamoto H, Murai H,
Koyama S and Kikuchi A: Axin, a negative regulator of the Wnt
signaling pathway, forms a complex with GSK-3beta and beta-catenin
and promotes GSK-3beta-dependent phosphorylation of beta-catenin.
EMBO J. 17:1371–1384. 1998. View Article : Google Scholar
|
|
36
|
Pennisi E: How a growth control path takes
a wrong turn to cancer. Science. 281:1438–1441. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Cui J, Zhou X, Liu Y, Tang Z and Romeih M:
Wnt signaling in hepatocellular carcinoma: analysis of mutation and
expression of beta-catenin, T-cell factor-4 and glycogen synthase
kinase 3-beta genes. J Gastroenterol Hepatol. 18:280–287. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Wei Y, Shen N, Wang Z, Yang G, Yi B, Yang
N, Qiu Y and Lu J: Sorafenib sensitizes hepatocellular carcinoma
cell to cisplatin via suppression of Wnt/β-catenin signaling. Mol
Cell Biochem. 381:139–144. 2013.PubMed/NCBI
|
|
39
|
He B, Kang Q, Yang J, Shang J, He T and
Zhou Q: Correlation between antitumor activity of berberine and the
inhibition of Wnt/beta-catenin signal pathway. Zhongguo Yaolixue
Tongbao. 21:1108–1111. 2005.(In Chinese).
|
|
40
|
Kumar DU and Devaraj H: Expression of Wnt
3a, β-catenin, cyclin D1 and PCNA in mouse dentate gyrus
subgranular zone (SGZ): a possible role of Wnt pathway in SGZ
neural stem cell proliferation. Folia Biol (Praha). 58:115–120.
2012.
|
|
41
|
Zhou CJ, Shi LJ, Fu LH, Wang L, Yu YC, Hu
CL and Chen L: Effect of matrine on expressions of SALL4 gene and
downstream target genes of Wnt/β-catenin signaling pathway in human
acute erythroleukemia cell line TF-1. Chin J Biol. 26:94–98.
2013.
|
|
42
|
Gao JT: Modulating action of matrine on
rat hepatic precancerous lesion and Wnt signaling transduction
pathway. http://d.g.wanfangdata.com.cn/Thesis_Y1354799.aspx.
Shijiazhuang: Heibei Medical University; 2008, (In Chinese).
|
|
43
|
Sparmann A and van Lohuizen M: Polycomb
silencers control cell fate, development and cancer. Nat Rev
Cancer. 6:846–856. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Valk-Lingbeek ME, Bruggeman SW and van
Lohuizen M: Stem cells and cancer; the polycomb connection. Cell.
118:409–418. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Park IK, Morrison SJ and Clarke MF: Bmi1,
stem cells, and senescence regulation. J Clin Invest. 113:175–179.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Fan L, Xu C, Wang C, Tao J, Ho C, Jiang L,
Gui B, Huang S, Evert M, Calvisi DF and Chen X: Bmi1 is required
for hepatic progenitor cell expansion and liver tumor development.
PLoS One. 7:e464722012. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Sawa M, Yamamoto K, Yokozawa T, Kiyoi H,
Hishida A, Kajiguchi T, Seto M, Kohno A, Kitamura K, Itoh Y, Asou
N, Hamajima N, Emi N and Naoe T: BMI1 is highly expressed in
M0-subtype acute myeloid leukemia. Int J Hematol. 82:42–47. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Silva J, García V, García JM, Peña C,
Domínguez G, Díaz R, Lorenzo Y, Hurtado A, Sánchez A and Bonilla F:
Circulating Bmi-1 mRNA as a possible prognostic factor for advanced
breast cancer patients. Breast Cancer Res. 9:R552007. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Liu JH, Song LB, Zhang X, Guo BH, Feng Y,
Li XX, Liao WT, Zeng MS and Huang KH: Bmi1 expression predicts
prognosis for patients with gastric carcinoma. J Surg Oncol.
97:267–272. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Sasaki M, Ikeda H, Itatsu K, Yamaguchi J,
Sawada S, Minato H, Ohta T and Nakanuma Y: The overexpression of
polycomb group proteins Bmi1 and EZH2 is associated with the
progression and aggressive biological behavior of hepatocellular
carcinoma. Lab Invest. 88:873–882. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Cao L, Bombard J, Cintron K, Sheedy J,
Weetall ML and Davis TW: BMI1 as a novel target for drug discovery
in cancer. J Cell Biochem. 112:2729–2741. 2011. View Article : Google Scholar : PubMed/NCBI
|
